Related Experiment Video
Updated: Aug 7, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Recommended and observed statin use among U.S. adults - National Health and Nutrition Examination Survey, 2011-2018
Angela M Thompson-Paul1, Cathleen Gillespie2, Hilary K Wall2
1U.S. Public Health Service, Rockville, MD, USA; Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Insights
The 2018 Cholesterol Guideline recommended fewer adults for statin therapy than the 2013 guideline, yet statin use remained suboptimal. Improved patient-clinician discussions are needed to boost treatment rates.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Clinical Guidelines
Background:
- The American College of Cardiology/American Heart Association (ACC/AHA) published blood cholesterol guidelines in 2013 and a multi-society guideline in 2018.
- These guidelines provide recommendations for the management of blood cholesterol and cardiovascular disease risk.
Purpose of the Study:
- To compare population-level estimates of statin recommendations and usage between the 2013 and 2018 cholesterol guidelines.
- To identify differences in guideline application across various demographic and patient management groups.
Main Methods:
- Analysis of National Health and Nutrition Examination Survey data (2011-2018) from 8,642 non-pregnant adults.
- Comparison of statin recommendation prevalence and use based on criteria from the 2013 and 2018 Cholesterol Guidelines.
Main Results:
- The 2018 Cholesterol Guideline recommended statins for an estimated 46.1 million adults, compared to 77.8 million under the 2013 guideline.
- Statin use among those recommended for treatment was similar under both guidelines (approximately 47%).
- Significant differences in recommendations and use were observed across demographic and patient management subgroups.
Conclusions:
- The 2018 Cholesterol Guideline algorithm resulted in a lower prevalence of statin recommendations but included more individuals for consideration via risk assessment and discussion.
- Statin utilization remained suboptimal (<50%) for individuals recommended for treatment under both guidelines.
- Enhancing patient-clinician risk discussions and shared decision-making is crucial for improving statin treatment rates.
Background:
The American College of Cardiology/American Heart Association Blood Cholesterol Guideline was published in 2013 (2013 Cholesterol Guideline) and the Multi-society Guideline on the Management of Blood Cholesterol in 2018 (2018 Cholesterol Guideline).
Objective:
To compare differences in population level estimates for statin recommendations and use between guidelines.
Methods:
Using four 2-year cycles from the National Health and Nutrition Examination Survey (2011-2018), we analyzed data from 8,642 non-pregnant adults aged ≥20 years with complete information for blood cholesterol measurements and other cardiovascular risk factors used to define treatment recommendations in the 2013 or 2018 Cholesterol Guidelines. We compared the prevalence of statin recommendations and use between the guidelines, overall and among patient management groups.
Results:
Under the 2013 Cholesterol Guideline, an estimated 77.8 million (33.6%) adults would be recommended statins, compared to 46.1 million (19.9%) recommended and 50.1 million (21.6%) considered for statins by the 2018 Cholesterol Guideline. Statin use among those recommended treatment was similar utilizing the 2018 Cholesterol Guideline (47.4%) compared to the 2013 Cholesterol Guideline (47.0%). Differences were observed across demographic and patient management groups.
Conclusion:
Compared to the 2013 Cholesterol Guideline, the prevalence of statin recommendations decreased utilizing the 2018 Cholesterol Guideline algorithm, though additional persons would be considered for treatment after risk factor assessment and patient-clinician discussion under the 2018 Cholesterol Guideline. Statin use was suboptimal (<50%) for those recommended treatment under either guideline. Optimizing patient-clinician risk discussions and shared decision making may be needed to improve treatment rates.
More Related Videos
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements